Zomac

Quick links to important sections

Zomac

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zomac

What is Zomac? Definition, Class, and Purpose

Property Description
Active ingredient Omeprazole (a substituted benzimidazole)
Form Delayed-release capsule, Enteric-coated tablet
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Reduction of excess stomach acid
Origin Synthetic

Zomac is a widely recognized trade name for a medication whose active ingredient is Omeprazole. It belongs to the pharmacological class of Proton Pump Inhibitors (PPIs). This class designates Zomac as an antisecretory compound, meaning its core function is to inhibit the secretion of acid in the stomach. Medications in this class are used to decrease the amount of acid the stomach makes. The medication is designed to provide relief from acid-related symptoms.

Chemically, Omeprazole is categorized as a synthetic substituted benzimidazole compound. Zomac is available in some regions as an over-the-counter (OTC) option, positioning it for direct patient access for common issues like frequent heartburn. As a PPI, Zomac is fundamentally used to provide significant and sustained relief by reducing the presence of excess stomach acid.

Composition, Origin, and Form

Omeprazole is the sole active ingredient in Zomac, making it a single active ingredient product. This compound is administered via the oral route in specialized pharmaceutical preparations, such as delayed-release capsules or enteric-coated tablets.

The specific formulation of the delayed-release capsule or enteric-coated tablet is crucial because Omeprazole is an acid-labile substance, meaning it would be rapidly degraded and deactivated if exposed directly to stomach acid. The protective coating ensures the active substance passes intact through the stomach and is released for absorption in the small intestine, delivering the dose to the parietal cells where it acts.

General Purpose of This Antisecretory Medicine

The general purpose of Zomac is to control and relieve symptoms associated with excess stomach acid by achieving a reduction in its production. It achieves this by the physiological action of blocking the final step of acid secretion, often referred to as the acid pump. By providing this sustained antisecretory action, Zomac helps to relieve discomfort and symptomatic feelings of acidity and heartburn, controlling the overall acidic environment in the upper digestive tract.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Zomac?

Possible Side Effects and Safety Information

The safety profile for Zomac (Omeprazole) is structured by governmental regulatory authorities to classify potential adverse reactions based on their observed frequency and the body system affected.

Common Adverse Reactions

The most frequently reported side effects in regulatory documents are generally related to the gastrointestinal system and include headache, abdominal pain, diarrhea, constipation, flatulence, and nausea/vomiting. The classification of these events as common means they are reported in between 1 and 10 out of every 100 patients.


Uncommon and Rare Reactions

Adverse reactions classified as uncommon include insomnia, dizziness, increased liver enzymes, dermatitis, and peripheral edema. Rare and very rare classifications document more serious effects across various systems. These include severe hypersensitivity reactions (e.g., angioedema), blood disorders (leukopenia, thrombocytopenia, agranulocytosis), and rare instances of tubulointerstitial nephritis and hepatic failure.


Safety Considerations and Duration of Use

Official labeling addresses safety patterns tied to the duration of use. The risk of bone fracture (hip, wrist, or spine) and deficiencies of Vitamin B-12 and magnesium (hypomagnesaemia) are noted as being associated with prolonged therapy, typically one year or longer. The drug's safety profile also includes high-level constraints: symptomatic relief from Zomac does not preclude the presence of gastric malignancy, and its use is associated with a potential increase in the risk of Clostridium difficile-associated diarrhea (CDAD).

Overdose and Emergency Response

Overdosage with Zomac (omeprazole) results in a profile of generally transient clinical manifestations, as documented in official prescribing information. The symptoms reported in cases of high exposure often involve the central nervous, gastrointestinal, and cardiovascular systems.

Documented signs include confusion, headache, drowsiness, and apathy. Gastrointestinal presentations typically involve nausea, vomiting, abdominal pain, and diarrhea. Cardiovascular manifestations such as tachycardia (unusually fast heartbeat), flushing, and increased sweating have also been noted.

The regulatory classification states that despite these manifestations, no serious clinical outcome has been reported in connection with omeprazole overdosage. This severity assessment confirms that reported effects are generally self-limiting.

In managing overdosage, the treatment is exclusively symptomatic and supportive. It is officially documented that no specific antidote is known for Zomac. Furthermore, the drug is extensively protein-bound and, consequently, not readily dialyzable, limiting procedural removal options.

Regardless of the reported severity, any suspected overdosage requires immediate action. Regulatory authorities mandate that individuals seek emergency medical help or contact a Poison Control Center right away for prompt evaluation and supportive care.

Therapeutic Uses of Zomac

Quick Facts: Zomac Therapeutic Use

  • Relieves Symptoms Associated with GERD: Zomac is indicated to provide relief from heartburn and acid regurgitation associated with gastroesophageal reflux disease (GERD).
  • Management of Erosive Esophagitis: The medication is used to support the healing process of the esophagus that has been damaged by acid reflux.
  • Addresses Ulcers: Zomac serves as a component of care for duodenal ulcers and gastric ulcers.
  • Supports Zollinger-Ellison Syndrome: The medication is used to manage this condition characterized by high acid production.

What Zomac Treats: Main Uses and Benefits

Zomac is a medication used in the management of conditions linked to the production of stomach acid. It is primarily used to address symptoms and facilitate healing for certain gastrointestinal issues.

Primary Therapeutic Domains

Treatment with Zomac is centered on several key areas of gastrointestinal health:

  • Gastroesophageal Reflux Disease (GERD): Zomac is indicated for the short-term management of GERD symptoms, including the feeling of heartburn and the backward flow of stomach contents. It assists in promoting an environment conducive to the relief of acid-related discomfort.
  • Healing of Erosive Esophagitis: For individuals experiencing injury to the lining of the esophagus due to acid exposure, Zomac is prescribed to support the healing and maintenance of the affected tissue.
  • Peptic Ulcer Conditions: The medication is used in therapeutic regimens for both duodenal ulcers and gastric ulcers to aid in managing these lesions.
  • Zollinger-Ellison Syndrome: Zomac is a component of the care plan for this specific, rare condition that presents with excessive gastric acid secretion, assisting in the overall management of symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Zomac?

The population eligibility for Zomac (Omeprazole) is strictly defined by official regulatory documentation, outlining groups for whom use is permitted, restricted, or absolutely prohibited.

Contraindicated Populations (Must Not Use)

Zomac is contraindicated in patients with a known hypersensitivity to omeprazole, to any component of the formulation, or to any substituted benzimidazoles (the drug class). Additionally, use is absolutely prohibited for patients receiving products that contain the antiretroviral agent rilpivirine.


Age and Physiological Restrictions

Use is established for adults and for pediatric patients aged 1 year and older for specific approved indications. However, safety and effectiveness are not established in children younger than 1 month of age.

Patients with hepatic impairment (liver disease) may require a dose adjustment due to altered drug metabolism, classifying their use as conditional.

Pregnancy and Lactation

Official labeling advises caution during pregnancy, permitting use only after a clinical evaluation determines that the benefit outweighs the potential risk. Use is generally not recommended during lactation as omeprazole is known to be excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation outlines specific pharmacokinetic and pharmacodynamic interaction patterns for Zomac (Omeprazole), based primarily on its role as a CYP2C19 inhibitor and its effect of elevating gastric pH. These interactions define several high-risk or prohibited combinations.

Documented High-Risk Combinations

Co-administered Substance Interaction Classification Official Outcome
Clopidogrel Avoid concomitant use Diminished antiplatelet activity due to reduced active metabolite formation.
Nelfinavir, Rilpivirine Contraindicated/Avoid use Significantly reduced plasma concentrations of antiretrovirals due to elevated gastric pH.

Pharmacokinetic and pH-Mediated Effects

As a CYP2C19 inhibitor, omeprazole elevates the plasma levels of co-administered drugs that are sensitive substrates, including Diazepam, Phenytoin, and Cilostazol, requiring monitoring. Conversely, drugs that induce CYP2C19/CYP3A4, such as Rifampin or the herbal product St. John's Wort, may reduce omeprazole concentrations and should be avoided.

The pH-raising effect of Zomac alters the absorption of drugs requiring an acidic environment, generally reducing the exposure of agents like Ketoconazole and Iron salts, while increasing the exposure of others, such as Digoxin.

Procedural and Timing Restrictions

Omeprazole must be stopped for at least 14 days before measuring Chromogranin A ( CgA) levels due to the risk of false-positive diagnostic results. Furthermore, administering Zomac and Clopidogrel at separate times does not diminish the officially documented interaction risk.

Mechanism of Action

How Zomac Works

Zomac (Omeprazole) exerts its antisecretory action by acting as a highly selective, permanent inhibitor of the final step of stomach acid production. The mechanism is defined by the selectivity and duration of its inhibitory effect.


1. Irreversible Inactivation of the Acid Pump

Zomac’s mechanism involves a unique interaction with the H^+/K^+-ATPase enzyme, the definitive gastric proton pump, situated in the parietal cells. The active form of the drug creates a covalent, irreversible bond with the enzyme. This binding permanently disables the pump, halting the exchange of hydrogen ions ( H^+), which are the molecular components of stomach acid. This profound molecular intervention leads directly to a prolonged reduction in the volume of secreted acid.


2. Selective, Acid-Triggered Prodrug Activation

The medication is administered as an inactive prodrug, which only transforms into its functional sulfenamide inhibitor form upon reaching the highly acidic environment within the parietal cell canaliculi ( pH < 4). This acid-dependent activation cascade ensures the drug is selectively concentrated at its intended site of action, which is critical for achieving a highly selective action confined to the system responsible for acid production.


3. Sustained Effect via Capacity Modulation

The irreversible binding mechanism means the inhibitory effect persists long after the drug has left the bloodstream. Full recovery of acid secretion is solely dependent on the synthesis of new proton pump enzymes by the parietal cells. This process of capacity modulation, where existing pumps are permanently retired, leads to a persistent elevation of intragastric pH throughout the dosing period.

Dosage and Administration Information

How to Use Zomac: Official Administration Guidelines

Zomac (Omeprazole) is primarily administered via the oral route using delayed-release capsules, tablets, or reconstituted powder, with an intravenous (IV) infusion available when oral intake is not possible. Standard dosing for conditions like ulcers and erosive esophagitis is typically 20 mg or 40 mg once daily. For rare, high-acid-producing conditions such as Zollinger-Ellison Syndrome, the daily dose may be significantly higher, requiring it to be divided into multiple administrations throughout the day.

Oral forms must be taken before eating, ideally about one hour prior to the morning meal. It is essential that capsules and tablets are swallowed whole to preserve the integrity of the delayed-release coating; they must not be crushed, split, or chewed. The IV form requires reconstitution and subsequent dilution, and must be administered as an infusion over a 20 to 30 minute period.

The frequency pattern is usually once daily, but is adjusted to twice daily for H. pylori combination therapy. Dose adjustment is not necessary for older adults or those with renal impairment, but a lower daily dose may be recommended for patients with severe hepatic impairment. If a dose is missed, it is generally advised to take it as soon as remembered; however, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed without taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zomac (Omeprazole)


Research Evidence for Symptom Relief in GERD

Studies focusing on symptomatic Gastroesophageal Reflux Disease (GERD) were conducted during periods of increased symptom activity, particularly heartburn and acid regurgitation. The primary research approach involved short-term randomized controlled trials (RCTs) where Zomac was studied, and researchers assessed patient-reported experiences. Findings describe patterns observed in the studies related to achieving a symptom-free state over short treatment intervals, typically four weeks or less. Research highlights changes measured during the study period, where Zomac was evaluated against inactive substances (placebo) or older classes of acid-reducing medicines. What remains uncertain is the full characterization of long-term outcomes for individuals managing symptomatic GERD alone, as follow-up durations were limited in many initial registration trials.


Evidence for Healing and Maintenance of Erosive Esophagitis

For individuals with erosive esophagitis (EE)—a condition associated with inflammatory or irritative states—research examined the tissue changes in the damaged esophageal lining. Studies included both adults and children with tissue damage confirmed by endoscopy. The main outcomes monitored were related to the rate and time documented for endoscopic tissue changes, such as complete re-epithelialization. Findings describe the proportion of patients where change was observed, following both short-term active treatment and during subsequent, long-term maintenance studies. Data for outcomes in long-term observational settings beyond 12 months remain insufficient. Research comparing Zomac against all contemporary treatment options is not universally comprehensive in the broader context of the existing data set.


Studies Addressing Duodenal and Gastric Ulcer Conditions

Zomac was studied for its role in managing both duodenal and benign gastric ulcers, which are conditions marked by functional limitations. Trials included adults with these conditions, often separating them based on the presence of the H. pylori bacteria. Research explored short-term changes in the size and depth of ulcer lesions, with endoscopic confirmation being the standard outcome axis for measuring closure. Studies also monitored patterns related to ulcer recurrence, especially when Zomac was evaluated in combination with antibiotics aimed at H. pylori eradication. Combination trials described patterns observed when used for H. pylori management, and subsequent collection of data on ulcer episodes.


Understanding Gaps and Uncertainties in the Research

Although a core body of evidence exists for the short-term use of Zomac, certainty remains low in several key areas. Specifically, there is limited information for long-term outcomes for most indications beyond the initial maintenance studies. Research comparing Zomac to newer acid-suppressing agents and optimized combination treatments is limited. Furthermore, the existing studies provide limited insight into the full range of responses across diverse patient characteristics, and subgroup findings are uncertain for specific comorbidity groups. The evidence highlights what is known—and what is still uncertain—about Zomac's patterns of use.

Key Studies & References

  1. Label: OMEPRAZOLE capsule - DailyMed (NIH/FDA)
  2. Longterm maintenance treatment with omeprazole in children with healed erosive oesophagitis: a prospective study
  3. A systematic review of Helicobacter pylori eradication treatment schedules in children

Frequently Asked Questions (FAQ)

Common questions about Zomac (FAQ)

Q: Can Zomac be taken at the same time as common vitamins or supplements?

A: Official safety information indicates that long-term use of Zomac is associated with potential deficiencies of key nutrients, particularly Vitamin B-12 and magnesium (hypomagnesaemia). Because of this, official guidelines generally state that patients should disclose the use of all vitamins and supplements to their healthcare provider.

Q: Does Zomac have any known interactions with alcohol?

A: Regulatory documents indicate that there is no significant drug interaction between Zomac and alcohol. However, since alcohol itself can increase the production of stomach acid, consuming alcohol may potentially counteract the medicine’s effects or aggravate the underlying acid-related symptoms.

Q: What are the most commonly reported side effects of Zomac?

A: According to official regulatory documentation, the most frequently reported adverse reactions are generally related to the gastrointestinal system. These common effects include headache, abdominal pain, diarrhea, flatulence (gas), nausea, and vomiting.

Q: Can Zomac cause changes in sleep patterns?

A: Official safety profiles classify insomnia (difficulty sleeping) as an uncommon adverse reaction associated with Zomac. This means it is reported in a small percentage of patients, according to regulatory data.

Q: What happens in the body when Zomac begins to wear off?

A: Zomac works by irreversibly binding to the acid pumps in the stomach. The inhibitory effect of a single dose lasts for about 72 hours. The full return of normal acid secretion depends on the body’s natural rate of synthesizing new acid pump enzymes, a process that can take several days.

Q: Is it possible to develop a tolerance to Zomac over time?

A: The drug’s mechanism involves irreversible binding to the acid pump; however, sudden cessation after long-term use has been reported to cause a temporary phenomenon called rebound acid hypersecretion.

Q: What does the research say about Zomac's safety profile?

A: Official safety warnings indicate that chronic use (typically one year or longer) is associated with potential risks such as nutrient deficiencies, osteoporotic fractures of the hip, wrist, or spine, and an increased risk of Clostridium difficile infection. These warnings have been issued by regulatory agencies like the FDA and EMA.

Q: What kind of research has been done on Zomac's effectiveness?

A: Studies on Zomac include short-term randomized controlled trials (RCTs) to assess patient-reported relief from symptoms like heartburn. They also include trials using endoscopic confirmation—a procedure to visually check the esophagus—to monitor the healing of tissue damage related to conditions like erosive esophagitis.

Q: Are there any known interactions between Zomac and herbal remedies?

A: The regulatory interaction documentation specifically notes interactions with the herbal product St. John’s Wort. Due to the potential for similar interactions, patients are generally stated to inform their healthcare provider of any herbal products they are using.

Q: Is it important to keep taking Zomac even if symptoms improve quickly?

A: For prescription uses, stopping the medication prematurely may allow the underlying condition or symptoms to worsen. Over-the-counter (OTC) use is typically limited to a 14-day course, as noted in the official product information.

Q: How quickly does Zomac typically start working?

A: The inhibitory effect of Zomac on stomach acid production is observed rapidly. Inhibition typically begins within one hour after the dose is taken, with the maximum acid-inhibitory effect typically observed within two hours.

Q: Is Zomac available as a generic medicine?

A: Yes, the active ingredient in Zomac, omeprazole, is widely available globally. It is sold both under its original brand name (Zomac) and as a lower-cost generic medicine.

Q: Are there different strengths or formulations of Zomac available?

A: Zomac is manufactured in several different forms, including specialized delayed-release capsules, tablets, and oral suspensions. It is also available in various strengths, depending on the formulation and intended use.

Q: Does Zomac carry any specific warnings for people with heart issues?

A: Regulatory and safety documents note that long-term use has been associated with an increased risk of cardiovascular events. Specific monitoring has been noted for patients with heart conditions who are taking antiplatelet agents, such as Clopidogrel, concurrently.

Q: Does Zomac have any effect on mental alertness or driving ability?

A: Official documentation indicates that Zomac generally does not affect a person's ability to drive a car or operate machinery. However, adverse reactions like dizziness are reported in the safety information.

Q: Is Zomac known to cause dependency or withdrawal symptoms?

A: Zomac is not known to cause chemical dependency. However, regulatory literature indicates that if the medication is stopped suddenly after a prolonged period of use, it can cause a temporary phenomenon called rebound acid hypersecretion, which results in the return of reflux symptoms.

Q: How long after stopping Zomac does it fully leave the system?

A: The medication is rapidly eliminated from the bloodstream once it is processed by the liver. The drug's plasma half-life is less than one hour, and it is generally cleared from the bloodstream within approximately three to four hours after the last dose.

Q: Does Zomac work for all people who have the condition it treats?

A: Studies and official information indicate that while Zomac is highly effective, there can be individual variability in patient response. Research shows that not all patients achieve a completely symptom-free state after the initial treatment course.

Q: What are the risks of using Zomac for a long period?

A: Long-term use is associated with a potential increased risk of bone fractures (hip, wrist, or spine) and deficiencies in Vitamin B-12 and magnesium. It is also associated with a potential increase in the risk of C. difficile-associated diarrhea.

Q: What is the typical timeframe for seeing the full effect of Zomac?

A: The drug works by building up its acid-suppressing effect over several doses. Although the inhibitory effect starts quickly, the full maximal acid suppression effect with daily use is typically achieved by the fourth day of continuous therapy.

Q: Does Zomac affect birth control pills or other hormonal medications?

A: According to official evidence-based rationale, there is no clinically significant interaction between Zomac and standard oral birth control pills. It is not expected to reduce the efficacy of hormonal contraceptives.

Q: Can I take Zomac if I have a history of allergic reactions to other drugs?

A: Official documentation notes that Zomac is contraindicated if a patient has a known hypersensitivity (allergy) to omeprazole, to any other component of the formulation, or to any other drug in the substituted benzimidazole class.

Q: Are there any special considerations for people with diabetes taking Zomac?

A: Official documentation describes specific interactions with certain diabetes medications, such as sulfonylureas. Zomac may increase the concentration of these drugs in the blood, which may be associated with an increased risk of hypoglycemic effects (low blood sugar).

Q: What happens if Zomac is taken past its expiration date?

A: Official guidelines state that Zomac should not be taken after the expiration date printed on the package. Taking the medicine after this date may be associated with reduced effectiveness or potency.

Q: Is Zomac available without a prescription in some countries?

A: In many regions, Zomac is available for sale over-the-counter (OTC) for managing common symptoms like frequent heartburn. Stronger doses or those used for certain medical indications still require a doctor's prescription.

Q: Why is monitoring necessary for some patients on Zomac?

A: Monitoring is recommended by regulatory bodies for specific patient groups, particularly those with heart disorders who are using antiplatelet agents (like Clopidogrel) concurrently, due to known drug interactions. Monitoring is also noted for certain other concomitant therapies.

Q: Can Zomac be taken with coffee or other caffeinated drinks?

A: While Zomac does not have a direct drug interaction with caffeine, beverages like coffee are highly acidic and can increase stomach acid production. It is noted that consuming highly acidic drinks too soon after taking Zomac may counteract its acid-reducing effect.

Q: What is the role of Zomac in managing a chronic condition?

A: For severe, chronic conditions such as severe Gastroesophageal Reflux Disease (GERD) or erosive esophagitis, Zomac may be required for long-term or even indefinite use. The role is to provide sustained control over acid production to prevent symptom recurrence and allow tissue healing.

Q: Is Zomac covered by most health insurance plans?

A: For patients in the United States, prescription versions of Zomac are generally covered by government programs such as Medicare Part D and by most commercial insurance plans. Coverage usually applies to the prescription form of the medication.

Q: Can people with liver conditions use Zomac?

A: Patients with liver impairment (hepatic impairment) may show reduced clearance of Zomac from their system. However, standard regulatory guidance generally indicates that use may be permitted for patients with liver disease.

How should Zomac be stored and disposed of?

How to Store and Dispose of Zomac

Storage Requirements

Zomac (Omeprazole) must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), with temporary excursions permitted up to 30 C (86 F). Due to its sensitivity, the medication must be stored out of the sight and reach of children and protected from moisture and, in some forms, light.

Regulatory labeling requires the product to be kept in the original container and, if applicable, the container must be kept tightly closed to maintain its stability. For bottled presentations, the medicine must be used within a specific period (such as 30 or 45 days) after the container is first opened.

Disposal Instructions

Unused or expired Zomac must be disposed of in accordance with local requirements. Government guidelines recommend utilizing a drug take-back program when available. If no take-back program exists, the medicine can be mixed with an undesirable substance (like dirt or used coffee grounds) and sealed in a container before disposal in the household trash, ensuring all identifying patient information is removed from the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zomac found in:

A-Z Index: